Evaluating the Heterogeneity of Advanced Prostate Cancer by <sup>18</sup>F‐DCFPyL and <sup>18</sup>F‐FDG PET/CT in a Prospective Cohort
Patients with DCFPyL-FDG+ lesions were more likely to have visceral metastases detected, be found in castration-resistant cohorts, have TP53 and/or RB1 mutations detected, and have poor therapeutic response compared to patients with DCFPyL+FDG± lesions. Therefore, dual-tracer (<sup>18</sup>F-DCFPyL and <sup>18</sup>F-FDG) PET/CT is recommended for patients with low PSMA expression incompatible with the true burden of the disease and those with TP53 and/or RB1 mutations to better evaluate the disease burden, tumor heterogeneity, and prognosis.
Authors
- ShangZhen Geng
- ShouZhen Chen (ORCID: https://orcid.org/0000-0003-1076-2992)
- Yuekai Li (ORCID: https://orcid.org/0000-0002-6082-754X)
- LinChen Lv
- Yong Wang
- Xin Li (ORCID: https://orcid.org/0000-0002-7844-6374)
- GuangHao Chen
- Benkang Shi (ORCID: https://orcid.org/0000-0002-6493-799X)
Institutions
- Qilu Hospital of Shandong University (CN)
Publication Details
- Journal
- The Prostate
- Published
- 2025-03-05
- DOI
- https://doi.org/10.1002/pros.24881
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.52